Injection frequency is one of the few things about these drugs a buyer can actually feel every week, and nobody has tested whether the day you take it matters — that absence is documented in injection day. How often you take it is a different question, and a phase 2b trial put an every-two-weeks injection against a weekly one [1].
On blood sugar the fortnightly drug did well. HbA1c fell 2.28 percentage points on bofanglutide 18 mg every two weeks against 1.60 on weekly semaglutide, a difference of -0.68 points (95% CI -1.04 to -0.33). The 12 and 24 mg fortnightly doses also beat the comparator, and hypoglycemia stayed rare across all arms with no severe episodes.
The comparator choice is by now a familiar pattern on this desk. Semaglutide 1 mg is the diabetes dose, not the 2.4 mg weight-management dose, and a favorable head-to-head against the lower arm keeps appearing in this literature — the same structural point made in cost per patient who actually hits the target and the super-responder brand comparison.
The authors list their own limitations plainly: open-label, short duration, and Chinese participants only. The trial was funded by Gan & Lee Pharmaceuticals, which makes the drug — stated in the paper, and ordinary for a phase 2b, but worth knowing. Twenty-four weeks is also too short to say anything about whether a fortnightly schedule helps people stay on treatment, which is the commercial question a fortnightly drug would need to answer.
Nothing here is buyable. Bofanglutide is not approved anywhere, and a phase 2b result is two expensive steps from a pharmacy. What it establishes is that dosing intervals longer than a week are pharmacologically achievable, which would change the arithmetic of what a year of treatment costs and how much of it people complete — the figures in two thirds stop within a year and what a GLP-1 actually costs are the ones it would have to move.